Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting.

Krüsi A, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg R, Montaner J, Wood E.

Antivir Ther. 2010;15(5):789-96. doi: 10.3851/IMP1614.

PMID:
20710061
[PubMed - indexed for MEDLINE]
2.

Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.

Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.

Antivir Ther. 2004 Oct;9(5):713-9.

PMID:
15535408
[PubMed - indexed for MEDLINE]
3.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.

PMID:
14517122
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):522-6.

PMID:
12679704
[PubMed - indexed for MEDLINE]
5.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.

Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, Wood E.

AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.

PMID:
21480010
[PubMed - indexed for MEDLINE]
6.

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.

Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS.

Drug Alcohol Depend. 2006 Sep 15;84(2):188-94. Epub 2006 Mar 20.

PMID:
16542797
[PubMed - indexed for MEDLINE]
7.

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.

Palepu A, Tyndall MW, Li K, Yip B, O'Shaughnessy MV, Schechter MT, Montaner JS, Hogg RS.

J Urban Health. 2003 Dec;80(4):667-75.

PMID:
14709714
[PubMed - indexed for MEDLINE]
Free PMC Article
8.
9.

Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.

Anema A, Kerr T, Milloy MJ, Feng C, Montaner JS, Wood E.

AIDS Care. 2014 Apr;26(4):459-65. doi: 10.1080/09540121.2013.832724. Epub 2013 Sep 9.

PMID:
24015838
[PubMed - indexed for MEDLINE]
10.

Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.

Weber R, Huber M, Rickenbach M, Furrer H, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Ledergerber B; Swiss HIV Cohort Study.

HIV Med. 2009 Aug;10(7):407-16. doi: 10.1111/j.1468-1293.2009.00701.x. Epub 2009 May 26.

PMID:
19490174
[PubMed - indexed for MEDLINE]
11.

Antiretroviral use among active injection-drug users: the role of patient-provider engagement and structural factors.

Knowlton AR, Arnsten JH, Eldred LJ, Wilkinson JD, Shade SB, Bohnert AS, Yang C, Wissow LS, Purcell DW.

AIDS Patient Care STDS. 2010 Jul;24(7):421-8. doi: 10.1089/apc.2009.0240.

PMID:
20578910
[PubMed - indexed for MEDLINE]
12.

Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.

Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, Tyndall M, Wood E.

Antivir Ther. 2004 Jun;9(3):407-14.

PMID:
15259903
[PubMed - indexed for MEDLINE]
13.

Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.

Wood E, Kerr T, Zhang R, Guillemi S, Palepu A, Hogg RS, Montaner JS.

HIV Med. 2008 Aug;9(7):503-7. doi: 10.1111/j.1468-1293.2008.00582.x. Epub 2008 May 15.

PMID:
18484977
[PubMed - indexed for MEDLINE]
14.

Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.

Rodríguez-Arenas MA, Jarrín I, del Amo J, Iribarren JA, Moreno S, Viciana P, Peña A, Sirvent JL, Vidal F, Lacruz J, Gutierrez F, Oteo JA, Asencio R, Castilla J, Hoyos SP; CoRIS-MD.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):715-23.

PMID:
16910826
[PubMed - indexed for MEDLINE]
15.

Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.

O'Connell JM, Braitstein P, Hogg RS, Yip B, Craib KJ, O'Shaughnessy MV, Montaner JS, Burdge DR.

Antivir Ther. 2003 Dec;8(6):569-76.

PMID:
14760890
[PubMed - indexed for MEDLINE]
16.

Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.

Kerr T, Marshall BD, Milloy MJ, Zhang R, Guillemi S, Montaner JS, Wood E.

Drug Alcohol Depend. 2012 Jul 1;124(1-2):108-12. doi: 10.1016/j.drugalcdep.2011.12.019. Epub 2012 Jan 14.

PMID:
22245312
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Highly active antiretroviral therapy and survival in HIV-infected injection drug users.

Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BD, Montaner JS.

JAMA. 2008 Aug 6;300(5):550-4. doi: 10.1001/jama.300.5.550.

PMID:
18677027
[PubMed - indexed for MEDLINE]
18.

Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors.

Knowlton AR, Arnsten JH, Gourevitch MN, Eldred L, Wilkinson JD, Rose CD, Buchanan A, Purcell DW; INSPIRE Study Team.

J Acquir Immune Defic Syndr. 2007 Nov 1;46 Suppl 2:S110-9. doi: 10.1097/QAI.0b013e31815767f8.

PMID:
18089980
[PubMed - indexed for MEDLINE]
19.

Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.

Tyndall MW, McNally M, Lai C, Zhang R, Wood E, Kerr T, Montaner JG.

Int J Drug Policy. 2007 Aug;18(4):281-7. Epub 2006 Dec 27.

PMID:
17689376
[PubMed - indexed for MEDLINE]
20.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group.

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4.

PMID:
18778390
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk